araag2/HINT huggingface dataset:
Clinical trial NCT00267553 (phase 3, status: terminated)
Conditions: breast neoplasms, neoplasms, hormone-dependent
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: atamestane, toremifene, letrozole
SMILES: CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C, CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Reason stopped: 
    this was a follow-on study to biomed 777-clp-029 which did not meet superiority endpoint
  
Eligibility criteria:

        Inclusion Criteria:

          -  To be eligible to receive continued treatment, subjects must remain eligible to
             receive study drug at the time of their last Biomed 777-CLP-29 visit

          -  To continue on survival follow-up, subjects must be in survival follow-up in study
             Biomed 777-CLP-29

          -  Written informed consent obtained for subjects who continue study drug treatment

        Exclusion Criteria:

          -  Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason

          -  Subjects for whom the investigator considers study participation is no longer in the
             best interest of those subjects.
Clinical trial NCT00095758 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: antidepressant + placebo, antidepressant + aripiprazole
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18-65 years old

          -  Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks
             in duration.

          -  Treatment history of an inadequate response to at least one and no more than three
             antidepressants.
Clinical trial NCT01315249 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol and glycopyrronium (qva149), placebo to fluticasone/salmeterol, fluticasone/salmeterol, placebo to indacaterol and glycopyrronium (qva149)
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Smoking history of at least 10 pack years

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate-to-severe as
             classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD]
             Guidelines, 2009)

          -  Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) >40% and < 80% of the
             predicted normal value and post-bronchodilator FEV1/Forced Vital Capacity (FVC) <70%

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation that required treatment with antibiotics,
             systemic steroids (oral or intravenous) or hospitalization in the last year.

          -  Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia.

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer (within last 5 years)

          -  Patients with a history of certain cardiovascular co-morbid conditions
Clinical trial NCT00675623 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: dimebon, dimebon, placebo
SMILES: CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1, CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Mild-to-Moderate Alzheimer's disease

          -  Probable AD (National Institute of Neurological and Communicative Disorders and Stroke
             and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and
             Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)

          -  MMSE score 10-24 inclusive

          -  Computerized tomography (CT) san or magnetic resonance imaging (MRI) consistent with
             AD

          -  Caregiver who cares for the patient at least 5 days per week

        Exclusion Criteria:

          -  Anti-dementia drugs including cholinesterase-inhibitors or N-methyl-D-aspartate
             receptor (NMDA) receptor antagonists within 90 days

          -  Other causes of dementia

          -  Other primary psychiatric or neurological disorders

          -  Unstable medical illnesses or significant hepatic or renal disease
Clinical trial NCT00091156 (phase 3, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the
             following stage criteria:

               -  Stage IIIB

                    -  Pleural fluid and/or supraclavicular nodes allowed provided patient is not
                       eligible for consolidation radiotherapy

               -  Stage IV disease

          -  No disease progression after 2-6 courses of prior platinum-containing first-line
             palliative induction chemotherapy

          -  Brain metastases allowed provided patients are asymptomatic after cranial irradiation
             completed at least 4 weeks ago

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Pulmonary

          -  No history, signs, or symptoms of clinically active interstitial lung disease

               -  Patients with chronic, stable, asymptomatic radiographic changes are eligible

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

          -  No other malignant disease within the past 5 years except basal cell skin cancer or
             adequately treated superficial carcinoma of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  See Disease Characteristics

          -  Recovered from prior chemotherapy (alopecia allowed)

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  Not specified

        Other

          -  No prior epidermal growth factor receptor inhibitors

          -  No concurrent administration of any of the following drugs:

               -  Phenytoin

               -  Carbamazepine

               -  Rifampin

               -  Phenobarbital

               -  Hypericum perforatum (St. John's wort)

          -  No other concurrent anticancer therapy

          -  No other concurrent experimental drugs
Clinical trial NCT00129220 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: olanzapine, haloperidol, placebo
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet the criteria for manic or mixed episodes according to the Diagnostic and
             Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) and
             have a diagnosis of "294.4x Bipolar I Disorder, Most Recent Episode Manic" or "296.6x
             Bipolar I Disorder, Most Recent Episode Mixed".

          -  Have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1
             and Visit 2.

        Exclusion Criteria:

          -  Have received an antidepressant or a psychostimulant within 5 days prior to Visit 1.

          -  The duration of the current episode is more than 90 days at Visit 1.

          -  Have a history or a diagnosis of diabetes mellitus.

          -  Have received any psychotropic medication within 2 days prior to Visit 2 (except for
             benzodiazepines).
Clinical trial NCT00298974 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: hydrocodone / acetaminophen extended release, placebo
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females ages 21 to 80

          -  If female, must be of non-child bearing potential or practicing birth control

          -  Has osteoarthritis of the hip or knee

          -  Requires therapeutic doses of medication for osteoarthritis pain

          -  Has sufficient pain to justify the use of around-the-clock opioids

        Exclusion Criteria:

          -  Is associated with any currently ongoing research study, or has previously
             participated in a Vicodin CR study

          -  Is allergic to or has had a serious reaction to hydrocodone, other opioids, or
             acetaminophen

          -  Cannot discontinue pain medications, even for the short time prior to the study start

          -  Has any clinically significant illness or recent injury, or has any significant
             laboratory abnormality, or has recently had major surgery

          -  Has a history of gastric bypass surgery or preexisting severe gastrointestinal
             narrowing, or history of diseases that may narrow the gastrointestinal tract

          -  Has a history of malnutrition or starvation

          -  Has a history of drug (licit or illicit) or alcohol abuse or addiction, or consumes
             more than 4 alcoholic drinks per day

          -  Has a history of a major depressive episode within the past 2 years, or requires
             treatment with certain drugs for depression, or has a history of major psychiatric
             disorder

          -  Pregnant or breastfeeding females

          -  Is incapacitated, bedridden or confined to a wheelchair

          -  Has initiated any new therapy or medication for OA within 1 month of screening

          -  Has had surgery, certain types of procedures, or received certain medications for
             osteoarthritis within a specified time frame

          -  Has other conditions that may cause pain, such as rheumatoid arthritis or gout
Clinical trial NCT00197080 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: ropinirole extended release (xr)
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosed with RLS using the International RLS Study Group Diagnostic Criteria with a
             total score of 15 or greater on the International RLS Rating Scale.

          -  Have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS
             symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than
             5:00PM.

        Exclusion criteria:

          -  Have secondary RLS.

          -  Have any medical conditions that may impact efficacy assessments or that may present a
             safety concern.
Clinical trial NCT00549302 (phase 3, status: completed)
Conditions: hypertension, pulmonary
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: tadalafil, tadalafil
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must have participated and discontinued in the previous PAH placebo controlled study
             due to clinical worsening on placebo or tadalafil 2.5 mg, 10mg, or 20 mg

          -  Must have completed Week 16 of the previous PAH study and had either no clinical
             worsening or became clinically worse at the Week 16 visit on placebo or tadalafil 2.5
             mg, 10mg, or 20 mg

          -  Females who have a negative urine pregnancy test and are willing to use 2 types of
             birth control

          -  Be 12 years or older (country specific regulations apply) with parental approval

        Exclusion Criteria:

          -  Participated in the placebo controlled study and had clinical worsening on 40 mg
             tadalafil

          -  Have left-sided heart disease

          -  Have a musculoskeletal disorder that limits being able to get around

          -  Nitrate use

          -  Certain current systemic treatments
Clinical trial NCT00000419 (phase 3, status: terminated)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: premarin and provera
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Female

          -  Unequivocal diagnosis of SLE

          -  Inactive disease or stable on 0.5 mg/kg/day or less of prednisone

          -  Chemical evidence of menopause or have stopped periods for at least 6 months

        Exclusion Criteria:

          -  Blood pressure >145/95 on three occasions

          -  Deep vein, arterial thrombosis or pulmonary embolus

          -  GPL >40; MPL >40; APL >50; dRVVT >37 sec

          -  APL antibody syndrome ever

          -  Gynecologic or breast cancer

          -  Hepatic dysfunction or liver tumors

          -  Diabetes mellitus (NOT due to steroids) with vascular disease

          -  Congenital hyperlipidemia

          -  Complicated migraine

          -  Severe disease activity (SLEDAI >12)

          -  Increase in SLEDAI >2 points in 3 months

          -  Unexplained vaginal bleeding

          -  Use of estrogen (HRT or OCP) for >1 month at any time after SLE diagnosis

          -  FSH <40

          -  Premenopausal myocardial infarction
Clinical trial NCT01235507 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, tocilizumab [roactemra/actemra]
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/= 18 years of age

          -  Active moderate to severe rheumatoid arthritis (RA)

          -  On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose
             of at least 15 mg/week for at least 6 weeks

          -  Oral corticosteroids must have been at stable dose of </= 10 mg/day prednisone (or
             equivalent) for at least 25 out of 28 days prior to first dose of study drug

          -  Body weight </= 150 kg

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months of study entry

          -  Rheumatic autoimmune disease other than RA

          -  Functional class IV according to American College of Rheumatology (ACR) classification

          -  Prior history of or current inflammatory joint disease other then RA

          -  Treatment with traditional DMARDs other than methotrexate within 1 month (for
             leflunomide 3 months) prior to baseline

          -  Treatment with any biologic drug that is used in the treatment or RA

          -  Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline

          -  Known active current or history of recurrent infection

          -  History of or currently active primary or secondary immunodeficiency

          -  Positive for HIV
Clinical trial NCT00105027 (phase 3, status: completed)
Conditions: macular edema, cystoid, retinal vein occlusion
ICD codes: H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: intravitreal triamcinolone injection, intravitreal triamcinolone injection
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with macular edema (swelling of the central part of the retina)
             associated with central retinal vein occlusion (CRVO) and branch retinal vein
             occlusion (BRVO).

          -  Individuals, 18 years of age or older, willing to provide consent may be eligible for
             the SCORE Study.

        Exclusion Criteria: refer to SCORE Study website at https://web.emmes.com/study/score/ for
        listing.
Clinical trial NCT00275132 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib hydrochloride, matched placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer

               -  Advanced disease (stage IIIB or IV)

               -  Diagnosis within 62 days prior to randomization

          -  Not suitable for first-line chemotherapy, as defined by the following criteria*:

               -  ECOG performance status 2-3

               -  ECOG performance status 0-1 AND creatinine clearance < 60 mL/min

          -  NOTE: *These criteria do not imply that all such patients are unsuitable for
             chemotherapy; patients are considered unsuitable on a case by case basis

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

          -  Estimated life expectancy of at least 8 weeks

          -  Able to take oral medication

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No severe uncontrolled infection

          -  No unstable angina

          -  No myocardial infarction within the past month

          -  No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative
             colitis)

          -  No acute renal failure

          -  Bilirubin < 2 times upper limit of normal (ULN)

          -  Transaminases < 2 times ULN (5 times ULN if liver metastases are present)

          -  Creatinine < 5 times ULN

          -  No evidence of other significant laboratory finding or uncontrolled medical illness
             that would interfere with study treatment or results comparison or render the patient
             at high risk from treatment complications

          -  No other prior or current malignant disease likely to interfere with study treatment
             or comparisons

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy

          -  No prior biological anticancer therapy (e.g., gefitinib, thalidomide, or cetuximab)

          -  No prior palliative radiotherapy

               -  Prior palliative radiotherapy to bone metastases allowed within the past 2 weeks

          -  No concurrent cyclooxygenase-2 inhibitors
Clinical trial NCT00360334 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, insulin glargine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  Currently being treated with the following: Dual or triple oral therapy - on a stable
             combination and dose for at least 3 months.

          -  HbA1c between 7.5% and 10.0%.

          -  BMI >27.

        Exclusion Criteria:

          -  Receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical and inhaled preparations) or have received such therapy within 2
             weeks immediately prior to study.

          -  Have participated in an interventional medical, surgical, or pharmaceutical study (a
             study in which a medical or surgical treatment was given) within 30 days prior to
             entry into the study.

          -  Treatment with the following medications: *Insulin as outpatient therapy within last 3
             months; *Meglitinides, or acarbose within the last 3 months; *Regular use of any drugs
             that directly affect gastrointestinal motility; *Any previous (study) therapy with
             exenatide or glucagon-like peptide-1 (GLP-1) analogue; *Anti-obesity agent use within
             the last 3 months.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.
Clinical trial NCT01302691 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: losartan potassium + hydrochlorothiazide + amlodipine besylate (mk-0954e), losartan potassium, amlodipine besylate, placebo to mk-0954e, placebo to losartan potassium, placebo to amlodipine besylate
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
Eligibility criteria:

        Inclusion criteria

          -  Participant has a diagnosis of essential hypertension.

          -  Participant is being treated with single or dual treatment for hypertension and will
             be able to discontinue the prior antihypertensive medication.

          -  Participant has a mean trough SiDBP of ≥ 90 mmHg and < 110 mmHg.

          -  Participant has a mean trough SiSBP of ≥ 140 mmHg and < 200 mmHg.

          -  Participant has no clinically significant abnormality at screening visit.

        Exclusion criteria

          -  Participant is currently taking > 2 antihypertensive medications.

          -  Participant has a history of significant multiple and/or severe allergies to
             ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug, and thiazide
             drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines).

          -  Participant is, at the time of signing informed consent, a user of recreational or
             illicit drugs or has had a recent history within the last year of drug or alcohol
             abuse or dependence.

          -  Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy
             test is positive at screening visit (Visit 1).

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within 30 days of signing informed consent.